Vascular and metabolic effects of SGLT2i and GLP-1 in heart failure patients
Alterations of endothelial function, inflammatory activation, and nitric oxide-cyclic guanosine monophosphate (NO-cGMP) pathway are involved in the pathophysiology of heart failure. Metabolic alterations have been studied in the myocardium of heart failure (HF) patients; alterations in ketone body a...
Gespeichert in:
| Veröffentlicht in: | Heart failure reviews 2023-05, Vol.28 (3), p.733-744 |
|---|---|
| Hauptverfasser: | , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 744 |
|---|---|
| container_issue | 3 |
| container_start_page | 733 |
| container_title | Heart failure reviews |
| container_volume | 28 |
| creator | Correale, Michele Lamacchia, Olga Ciccarelli, Michele Dattilo, Giuseppe Tricarico, Lucia Brunetti, Natale Daniele |
| description | Alterations of endothelial function, inflammatory activation, and nitric oxide-cyclic guanosine monophosphate (NO-cGMP) pathway are involved in the pathophysiology of heart failure. Metabolic alterations have been studied in the myocardium of heart failure (HF) patients; alterations in ketone body and amino acid/protein metabolism have been described in patients affected by HF, as well as mitochondrial dysfunction and other modified metabolic signaling. However, their possible contributions toward cardiac function impairment in HF patients are not completely known. Recently, sodium-glucose co-transporter 2 inhibitors (SGLT2i) and glucagon-like peptide-1 (GLP-1) receptor agonists (RAs) have emerged as a new class of drugs designed to treat patients with type 2 diabetes (T2D), but have also been shown to be protective against HF-related events and CV mortality. To date, the protective cardiovascular effects of these drugs in patients with and without T2D are not completely understood and several mechanisms have been proposed. In this review, we discuss on vascular and metabolic effects of SGLT2i and GLP-1 in HF patients. |
| doi_str_mv | 10.1007/s10741-021-10157-y |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_journals_2806688291</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2806688291</sourcerecordid><originalsourceid>FETCH-LOGICAL-c342t-61360099a2a2b3abb1ff141011fdf0d069c8d0a57fea97cc42dc95e959816aa53</originalsourceid><addsrcrecordid>eNp9kEtPwzAQhC0EoqXwBzggS5wN60cePqIKClIkkChcLcexIVWaFDs59N9jmvI4cdqVZnZG-yF0TuGKAmTXgUImKAFGCQWaZGR7gKZxcpJxxg7_7BN0EsIKAIQUcIwmXPBMMiamqHjVwQyN9li3FV7bXpddUxtsnbOmD7hz-HlRLFm90xfFE6G4bvG71b7HTtfN4C3e6L62bR9O0ZHTTbBn-zlDL3e3y_k9KR4XD_ObghguWE9SylMAKTXTrOS6LKlzVMQXqKscVJBKk1egk8xZLTNjBKuMTKxMZE5TrRM-Q5dj7sZ3H4MNvVp1g29jpWI5pGmeM0mji40u47sQvHVq4-u19ltFQX0BVCNAFQGqHUC1jUcX--ihXNvq5-SbWDTw0RCi1L5Z_9v9T-wnLox5-g</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2806688291</pqid></control><display><type>article</type><title>Vascular and metabolic effects of SGLT2i and GLP-1 in heart failure patients</title><source>MEDLINE</source><source>SpringerLink</source><creator>Correale, Michele ; Lamacchia, Olga ; Ciccarelli, Michele ; Dattilo, Giuseppe ; Tricarico, Lucia ; Brunetti, Natale Daniele</creator><creatorcontrib>Correale, Michele ; Lamacchia, Olga ; Ciccarelli, Michele ; Dattilo, Giuseppe ; Tricarico, Lucia ; Brunetti, Natale Daniele</creatorcontrib><description>Alterations of endothelial function, inflammatory activation, and nitric oxide-cyclic guanosine monophosphate (NO-cGMP) pathway are involved in the pathophysiology of heart failure. Metabolic alterations have been studied in the myocardium of heart failure (HF) patients; alterations in ketone body and amino acid/protein metabolism have been described in patients affected by HF, as well as mitochondrial dysfunction and other modified metabolic signaling. However, their possible contributions toward cardiac function impairment in HF patients are not completely known. Recently, sodium-glucose co-transporter 2 inhibitors (SGLT2i) and glucagon-like peptide-1 (GLP-1) receptor agonists (RAs) have emerged as a new class of drugs designed to treat patients with type 2 diabetes (T2D), but have also been shown to be protective against HF-related events and CV mortality. To date, the protective cardiovascular effects of these drugs in patients with and without T2D are not completely understood and several mechanisms have been proposed. In this review, we discuss on vascular and metabolic effects of SGLT2i and GLP-1 in HF patients.</description><identifier>ISSN: 1573-7322</identifier><identifier>ISSN: 1382-4147</identifier><identifier>EISSN: 1573-7322</identifier><identifier>DOI: 10.1007/s10741-021-10157-y</identifier><identifier>PMID: 34379224</identifier><language>eng</language><publisher>New York: Springer US</publisher><subject>Amino acids ; Cardiology ; Cardiovascular Diseases ; Cardiovascular System ; Congestive heart failure ; Cyclic GMP ; Diabetes mellitus (non-insulin dependent) ; Diabetes Mellitus, Type 2 - complications ; Diabetes Mellitus, Type 2 - drug therapy ; GLP-1 receptor agonists ; Glucagon ; Glucagon-Like Peptide 1 ; Glucose transporter ; Heart Failure ; Humans ; Inflammation ; Medicine ; Medicine & Public Health ; Metabolism ; Mitochondria ; Myocardium ; Nitric oxide ; Protein turnover ; Sodium-Glucose Transporter 2 Inhibitors - pharmacology ; Sodium-Glucose Transporter 2 Inhibitors - therapeutic use</subject><ispartof>Heart failure reviews, 2023-05, Vol.28 (3), p.733-744</ispartof><rights>The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature 2021</rights><rights>2021. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.</rights><rights>The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature 2021.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c342t-61360099a2a2b3abb1ff141011fdf0d069c8d0a57fea97cc42dc95e959816aa53</citedby><cites>FETCH-LOGICAL-c342t-61360099a2a2b3abb1ff141011fdf0d069c8d0a57fea97cc42dc95e959816aa53</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s10741-021-10157-y$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s10741-021-10157-y$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>314,776,780,27901,27902,41464,42533,51294</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/34379224$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Correale, Michele</creatorcontrib><creatorcontrib>Lamacchia, Olga</creatorcontrib><creatorcontrib>Ciccarelli, Michele</creatorcontrib><creatorcontrib>Dattilo, Giuseppe</creatorcontrib><creatorcontrib>Tricarico, Lucia</creatorcontrib><creatorcontrib>Brunetti, Natale Daniele</creatorcontrib><title>Vascular and metabolic effects of SGLT2i and GLP-1 in heart failure patients</title><title>Heart failure reviews</title><addtitle>Heart Fail Rev</addtitle><addtitle>Heart Fail Rev</addtitle><description>Alterations of endothelial function, inflammatory activation, and nitric oxide-cyclic guanosine monophosphate (NO-cGMP) pathway are involved in the pathophysiology of heart failure. Metabolic alterations have been studied in the myocardium of heart failure (HF) patients; alterations in ketone body and amino acid/protein metabolism have been described in patients affected by HF, as well as mitochondrial dysfunction and other modified metabolic signaling. However, their possible contributions toward cardiac function impairment in HF patients are not completely known. Recently, sodium-glucose co-transporter 2 inhibitors (SGLT2i) and glucagon-like peptide-1 (GLP-1) receptor agonists (RAs) have emerged as a new class of drugs designed to treat patients with type 2 diabetes (T2D), but have also been shown to be protective against HF-related events and CV mortality. To date, the protective cardiovascular effects of these drugs in patients with and without T2D are not completely understood and several mechanisms have been proposed. In this review, we discuss on vascular and metabolic effects of SGLT2i and GLP-1 in HF patients.</description><subject>Amino acids</subject><subject>Cardiology</subject><subject>Cardiovascular Diseases</subject><subject>Cardiovascular System</subject><subject>Congestive heart failure</subject><subject>Cyclic GMP</subject><subject>Diabetes mellitus (non-insulin dependent)</subject><subject>Diabetes Mellitus, Type 2 - complications</subject><subject>Diabetes Mellitus, Type 2 - drug therapy</subject><subject>GLP-1 receptor agonists</subject><subject>Glucagon</subject><subject>Glucagon-Like Peptide 1</subject><subject>Glucose transporter</subject><subject>Heart Failure</subject><subject>Humans</subject><subject>Inflammation</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Metabolism</subject><subject>Mitochondria</subject><subject>Myocardium</subject><subject>Nitric oxide</subject><subject>Protein turnover</subject><subject>Sodium-Glucose Transporter 2 Inhibitors - pharmacology</subject><subject>Sodium-Glucose Transporter 2 Inhibitors - therapeutic use</subject><issn>1573-7322</issn><issn>1382-4147</issn><issn>1573-7322</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>8G5</sourceid><sourceid>BENPR</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><recordid>eNp9kEtPwzAQhC0EoqXwBzggS5wN60cePqIKClIkkChcLcexIVWaFDs59N9jmvI4cdqVZnZG-yF0TuGKAmTXgUImKAFGCQWaZGR7gKZxcpJxxg7_7BN0EsIKAIQUcIwmXPBMMiamqHjVwQyN9li3FV7bXpddUxtsnbOmD7hz-HlRLFm90xfFE6G4bvG71b7HTtfN4C3e6L62bR9O0ZHTTbBn-zlDL3e3y_k9KR4XD_ObghguWE9SylMAKTXTrOS6LKlzVMQXqKscVJBKk1egk8xZLTNjBKuMTKxMZE5TrRM-Q5dj7sZ3H4MNvVp1g29jpWI5pGmeM0mji40u47sQvHVq4-u19ltFQX0BVCNAFQGqHUC1jUcX--ihXNvq5-SbWDTw0RCi1L5Z_9v9T-wnLox5-g</recordid><startdate>20230501</startdate><enddate>20230501</enddate><creator>Correale, Michele</creator><creator>Lamacchia, Olga</creator><creator>Ciccarelli, Michele</creator><creator>Dattilo, Giuseppe</creator><creator>Tricarico, Lucia</creator><creator>Brunetti, Natale Daniele</creator><general>Springer US</general><general>Springer Nature B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7QP</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>M2O</scope><scope>MBDVC</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>Q9U</scope></search><sort><creationdate>20230501</creationdate><title>Vascular and metabolic effects of SGLT2i and GLP-1 in heart failure patients</title><author>Correale, Michele ; Lamacchia, Olga ; Ciccarelli, Michele ; Dattilo, Giuseppe ; Tricarico, Lucia ; Brunetti, Natale Daniele</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c342t-61360099a2a2b3abb1ff141011fdf0d069c8d0a57fea97cc42dc95e959816aa53</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2023</creationdate><topic>Amino acids</topic><topic>Cardiology</topic><topic>Cardiovascular Diseases</topic><topic>Cardiovascular System</topic><topic>Congestive heart failure</topic><topic>Cyclic GMP</topic><topic>Diabetes mellitus (non-insulin dependent)</topic><topic>Diabetes Mellitus, Type 2 - complications</topic><topic>Diabetes Mellitus, Type 2 - drug therapy</topic><topic>GLP-1 receptor agonists</topic><topic>Glucagon</topic><topic>Glucagon-Like Peptide 1</topic><topic>Glucose transporter</topic><topic>Heart Failure</topic><topic>Humans</topic><topic>Inflammation</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Metabolism</topic><topic>Mitochondria</topic><topic>Myocardium</topic><topic>Nitric oxide</topic><topic>Protein turnover</topic><topic>Sodium-Glucose Transporter 2 Inhibitors - pharmacology</topic><topic>Sodium-Glucose Transporter 2 Inhibitors - therapeutic use</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Correale, Michele</creatorcontrib><creatorcontrib>Lamacchia, Olga</creatorcontrib><creatorcontrib>Ciccarelli, Michele</creatorcontrib><creatorcontrib>Dattilo, Giuseppe</creatorcontrib><creatorcontrib>Tricarico, Lucia</creatorcontrib><creatorcontrib>Brunetti, Natale Daniele</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Calcium & Calcified Tissue Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>ProQuest research library</collection><collection>Research Library (Corporate)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest Central Basic</collection><jtitle>Heart failure reviews</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Correale, Michele</au><au>Lamacchia, Olga</au><au>Ciccarelli, Michele</au><au>Dattilo, Giuseppe</au><au>Tricarico, Lucia</au><au>Brunetti, Natale Daniele</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Vascular and metabolic effects of SGLT2i and GLP-1 in heart failure patients</atitle><jtitle>Heart failure reviews</jtitle><stitle>Heart Fail Rev</stitle><addtitle>Heart Fail Rev</addtitle><date>2023-05-01</date><risdate>2023</risdate><volume>28</volume><issue>3</issue><spage>733</spage><epage>744</epage><pages>733-744</pages><issn>1573-7322</issn><issn>1382-4147</issn><eissn>1573-7322</eissn><abstract>Alterations of endothelial function, inflammatory activation, and nitric oxide-cyclic guanosine monophosphate (NO-cGMP) pathway are involved in the pathophysiology of heart failure. Metabolic alterations have been studied in the myocardium of heart failure (HF) patients; alterations in ketone body and amino acid/protein metabolism have been described in patients affected by HF, as well as mitochondrial dysfunction and other modified metabolic signaling. However, their possible contributions toward cardiac function impairment in HF patients are not completely known. Recently, sodium-glucose co-transporter 2 inhibitors (SGLT2i) and glucagon-like peptide-1 (GLP-1) receptor agonists (RAs) have emerged as a new class of drugs designed to treat patients with type 2 diabetes (T2D), but have also been shown to be protective against HF-related events and CV mortality. To date, the protective cardiovascular effects of these drugs in patients with and without T2D are not completely understood and several mechanisms have been proposed. In this review, we discuss on vascular and metabolic effects of SGLT2i and GLP-1 in HF patients.</abstract><cop>New York</cop><pub>Springer US</pub><pmid>34379224</pmid><doi>10.1007/s10741-021-10157-y</doi><tpages>12</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1573-7322 |
| ispartof | Heart failure reviews, 2023-05, Vol.28 (3), p.733-744 |
| issn | 1573-7322 1382-4147 1573-7322 |
| language | eng |
| recordid | cdi_proquest_journals_2806688291 |
| source | MEDLINE; SpringerLink |
| subjects | Amino acids Cardiology Cardiovascular Diseases Cardiovascular System Congestive heart failure Cyclic GMP Diabetes mellitus (non-insulin dependent) Diabetes Mellitus, Type 2 - complications Diabetes Mellitus, Type 2 - drug therapy GLP-1 receptor agonists Glucagon Glucagon-Like Peptide 1 Glucose transporter Heart Failure Humans Inflammation Medicine Medicine & Public Health Metabolism Mitochondria Myocardium Nitric oxide Protein turnover Sodium-Glucose Transporter 2 Inhibitors - pharmacology Sodium-Glucose Transporter 2 Inhibitors - therapeutic use |
| title | Vascular and metabolic effects of SGLT2i and GLP-1 in heart failure patients |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-04T15%3A58%3A24IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Vascular%20and%20metabolic%20effects%20of%20SGLT2i%20and%20GLP-1%20in%20heart%20failure%20patients&rft.jtitle=Heart%20failure%20reviews&rft.au=Correale,%20Michele&rft.date=2023-05-01&rft.volume=28&rft.issue=3&rft.spage=733&rft.epage=744&rft.pages=733-744&rft.issn=1573-7322&rft.eissn=1573-7322&rft_id=info:doi/10.1007/s10741-021-10157-y&rft_dat=%3Cproquest_cross%3E2806688291%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2806688291&rft_id=info:pmid/34379224&rfr_iscdi=true |